SCHEMBL4816673

SCHEMBL4816673

CCOC(=O)C(C)c1[c]cccc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PIN1 Q13526 1/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 2/20 0.41
NPC1 O15118 1/20 0.41
MMP8 P22894 2/20 0.40
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
APEX1 P27695 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11409716 0.90 NLRP3 (0.45) TSHRSMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL11281869 0.90 LMNA (0.40) TSHRLMNASMN1; SMN2PIN1KMT2A
SCHEMBL11416335 0.83 SMN1; SMN2 (0.39) TSHRSMN1; SMN2KMT2AALDH1A1GAA
SCHEMBL998674 0.83 KMT2A (0.43) TSHRKMT2AALDH1A1HPGDMEN1
SCHEMBL11286164 0.83 ALDH1A1 (0.49) LMNAKMT2AALDH1A1TDP1L3MBTL1
SCHEMBL11285004 0.79 L3MBTL1 (0.44) LMNASMN1; SMN2KMT2AALDH1A1GAA
SCHEMBL4016238 0.77 PTGS2 (0.46) TSHRLMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL11043246 0.75 EPHX1 (0.37) TSHRKMT2ATDP1L3MBTL1POLB
SCHEMBL11276127 0.75 GAA (0.41) SMN1; SMN2ALDH1A1GAAHPGDNPC1
SCHEMBL3539652 0.75 SLC6A2 (0.44) TSHRLMNAKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7323563-B2 Hydroxamic acid derivatives as antibacterials BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2008-01-29 US disclosed
EP-1754477-A2 Hydroxamic acid derivatives as antibacterials Vernalis (Oxford) Limited (GB) 2007-02-21 EP disclosed
EP-1079819-B1 HYDROXAMIC ACID DERIVATIVES AS ANTIBACTERIALS VERNALIS OXFORD LTD (GB) 2006-12-06 EP disclosed
US-20060211732-A1 Hydroxamic acid derivatives as antibacterials BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2006-09-21 US disclosed
US-6992190-B2 Hydroxamic acid derivatives as antibacterials BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2006-01-31 US disclosed
US-20020198241-A1 Hydroxamic acid derivatives as antibacterials BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2002-12-26 US disclosed
US-6441042-B1 HYDROXYAMIDES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2002-08-27 US disclosed
US-4348410-A Cyclohexane carboxylic acid derivatives NIPPON CHEMIPHAR CO., LTD. (JP) 1982-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211732-A1 Hydroxamic acid derivatives as antibacterials SLC7A1, EGLN2, PIGS TSHR 2357/4885LMNA 3846/4885SMN1; SMN2 1425/4885
US-20020198241-A1 Hydroxamic acid derivatives as antibacterials SLC7A1, EGLN2, PIGS TSHR 2326/4885LMNA 3748/4885SMN1; SMN2 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.